A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-03 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
=== Ratings and awards === In 2005 Hibiscus was one of three restaurants to be awarded three-stars by the Egon Ronay Restaurant Guide, along with The Waterside Inn and Restaurant Tom Aikens, and was named Ronay's Restaurant of the Year. The restaurant made its first entry in the World's 50 Best Restaurants in 2010, ranked in 49th place and one of three British restaurants in the list; the following year it moved up to 43rd. The Good Food Guide ranked Hibiscus as the eighth-best restaurant in the UK in its 2013 guide. The restaurant has been given five AA Rosettes by The Automobile Association.
===== MeSH D08.811.913.696 – phosphotransferases (EC 2.7) ===== MeSH D08.811.913.696.175 – diphosphotransferases MeSH D08.811.913.696.175.300 – gtp pyrophosphokinase MeSH D08.811.913.696.175.650 – ribose-phosphate pyrophosphokinase MeSH D08.811.913.696.175.825 – thiamin pyrophosphokinase MeSH D08.811.913.696.310 – myosin type iii MeSH D08.811.913.696.445 – nucleotidyltransferases MeSH D08.811.913.696.445.035 – n-acylneuraminate cytidylyltransferase MeSH D08.811.913.696.445.184 – choline-phosphate cytidylyltransferase MeSH D08.811.913.696.445.308 – dna nucleotidyltransferases MeSH D08.811.913.696.445.308.300 – dna-directed dna polymerase MeSH D08.811.913.696.445.308.300.112 – dna polymerase beta MeSH D08.811.913.696.445.308.300.225 – dna polymerase i MeSH D08.811.913.696.445.308.300.230 – dna polymerase ii MeSH D08.811.913.696.445.308.300.235 – dna polymerase iii MeSH D08.811.913.696.445.308.300.750 – RNA-directed dna polymerase MeSH D08.811.913.696.445.308.300.750.375 – hiv-1 reverse transcriptase MeSH D08.811.913.696.445.308.300.750.750 – telomerase MeSH D08.811.913.696.445.308.300.875 – taq polymerase MeSH D08.811.913.696.445.308.325 – dna nucleotidylexotransferase MeSH D08.811.913.696.445.400 – glucose-1-phosphate adenylyltransferase MeSH D08.811.913.696.445.600 – nicotinamide-nucleotide adenylyltransferase MeSH D08.811.913.696.445.625 – 2',5'-oligoadenylate synthetase MeSH D08.811.913.696.445.650 – polynucleotide adenylyltransferase MeSH D08.811.913.696.445.692 – rec a recombinases MeSH D08.811.913.696.445.735 – rna nucleotidyltransferases MeSH D08.811.913.696.445.735.265 – dna, catalytic MeSH D08.811.913.696.445.735.270 – dna-directed rna polymerases MeSH D08.811.913.696.445.735.270.375 – dna primase MeSH D08.811.913.696.445.735.270.750 – rna polymerase i MeSH D08.811.913.696.445.735.270.762 – rna polymerase ii MeSH D08.811.913.696.445.735.270.775 – rna polymerase iii MeSH D08.811.913.696.445.735.270.887 – rna polymerase sigma 54 MeSH D08.811.913.696.445.735.532 – polyribonucleotide nucleotidyltransferase MeSH D08.811.913.696.445.735.630 – q beta replicase MeSH D08.811.913.696.445.735.720 – rna helicases MeSH D08.811.913.696.445.735.720.500 – eukaryotic initiation factor-4a MeSH D08.811.913.696.445.735.780 – rna replicase MeSH D08.811.913.696.445.735.917 – rna, ribosomal, self-splicing MeSH D08.811.913.696.445.800 – sulfate adenylyltransferase MeSH D08.811.913.696.445.825 – transposases MeSH D08.811.913.696.445.825.500 – hiv integrase MeSH D08.811.913.696.445.837 – transposon resolvases MeSH D08.811.913.696.445.850 – UDP-glucose—hexose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.875 – UTP—glucose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.900 – UTP—hexose-1-phosphate uridylyltransferase MeSH D08.811.913.696.445.950 – vdj recombinases MeSH D08.811.913.696.620 – phosphotransferases (alcohol group acceptor) MeSH D08.811.913.696.620.010 – adenosine kinase MeSH D08.811.913.696.620.155 – choline kinase MeSH D08.811.913.696.620.175 – deoxycytidine kinase MeSH D08.811.913.696.620.200 – diacylglycerol kinase MeSH D08.811.913.696.620.225 – fructokinases MeSH D08.811.913.696.620.225.850 – phosphofructokinases MeSH D08.811.913.696.620.225.850.500 – phosphofructokinase-1 MeSH D08.811.913.696.620.225.850.500.249 – phosphofructokinase-1, liver type MeSH D08.811.913.696.620.225.850.500.500 – phosphofructokinase-1, muscle type MeSH D08.811.913.696.620.225.850.500.750 – phosphofructokinase-1, type c MeSH D08.811.913.696.620.225.850.750 – phosphofructokinase-2 MeSH D08.811.913.696.620.240 – galactokinase MeSH D08.811.913.696.620.250 – glucokinase MeSH D08.811.913.696.620.275 – glycerol kinase MeSH D08.811.913.696.620.300 – hexokinase MeSH D08.811.913.696.620.475 – kanamycin kinase MeSH D08.811.913.696.620.525 – 1-phosphatidylinositol 3-kinase MeSH D08.811.913.696.620.550 – 1-phosphatidylinositol 4-kinase MeSH D08.811.913.696.620.650 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.913.696.620.680 – polynucleotide 5'-hydroxyl-kinase MeSH D08.811.913.696.620.682 – protein kinases MeSH D08.811.913.696.620.682.650 – phosphorylase kinase MeSH D08.811.913.696.620.682.700 – protein-serine-threonine kinases MeSH D08.811.913.696.620.682.700.062 – activin receptors MeSH D08.811.913.696.620.682.700.062.500 – activin receptors, type i MeSH D08.811.913.696.620.682.700.062.750 – activin receptors, type ii MeSH D08.811.913.696.620.682.700.109 – bone morphogenetic protein receptors MeSH D08.811.913.696.620.682.700.109.500 – bone morphogenetic protein receptors, type i MeSH D08.811.913.696.620.682.700.109.750 – bone morphogenetic protein receptors, type ii MeSH D08.811.913.696.620.682.700.125 – ca(2+)-calmodulin dependent protein kinase MeSH D08.811.913.696.620.682.700.125.500 – myosin-light-chain kinase MeSH D08.811.913.696.620.682.700.140 – casein kinases MeSH D08.811.913.696.620.682.700.140.300 – casein kinase i MeSH D08.811.913.696.620.682.700.140.300.100 – casein kinase ialpha MeSH D08.811.913.696.620.682.700.140.300.200 – casein kinase idelta MeSH D08.811.913.696.620.682.700.140.300.300 – casein kinase iepsilon MeSH D08.811.913.696.620.682.700.140.600 – casein kinase ii MeSH D08.811.913.696.620.682.700.150 – cyclic nucleotide-regulated protein kinases MeSH D08.811.913.696.620.682.700.150.125 – cyclic amp-dependent protein kinases MeSH D08.811.913.696.620.682.700.150.125.500 – beta-adrenergic-receptor kinase MeSH D08.811.913.696.620.682.700.150.150 – cyclic gmp-dependent protein kinases MeSH D08.811.913.696.620.682.700.150.575 – protamine kinase MeSH D08.811.913.696.620.682.700.200 – cyclin-dependent kinases MeSH D08.811.913.696.620.682.700.200.067 – cdc2-cdc28 kinases MeSH D08.811.913.696.620.682.700.200.067.249 – cdc2 protein kinase MeSH D08.811.913.696.620.682.700.200.067.500 – cdc28 protein kinase, s cerevisiae MeSH D08.811.913.696.620.682.700.200.067.875 – cyclin-dependent kinase 5 MeSH D08.811.913.696.620.682.700.200.067.900 – cyclin-dependent kinase 9 MeSH D08.811.913.696.620.682.700.200.323 – cyclin-dependent kinase 2 MeSH D08.811.913.696.620.682.700.200.451 – cyclin-dependent kinase 4 MeSH D08.811.913.696.620.682.700.200.515 – cyclin-dependent kinase 6 MeSH D08.811.913.696.620.682.700.200.580 – maturation-promoting factor MeSH D08.811.913.696.620.682.700.200.580.500 – cdc2 protein kinase MeSH D08.811.913.696.620.682.700.250 – dna-activated protein kinase MeSH D08.811.913.696.620.682.700.300 – eif-2 kinase MeSH D08.811.913.696.620.682.700.429 – glycogen synthase kinases MeSH D08.811.913.696.620.682.700.429.500 – glycogen synthase kinase 3 MeSH D08.811.913.696.620.682.700.494 – i-kappa B kinase MeSH D08.811.913.696.620.682.700.559 – map kinase kinase kinases MeSH D08.811.913.696.620.682.700.559.100 – map kinase kinase kinase 1 MeSH D08.811.913.696.620.682.700.559.200 – map kinase kinase kinase 2 MeSH D08.811.913.696.620.682.700.559.300 – map kinase kinase kinase 3 MeSH D08.811.913.696.620.682.700.559.400 – map kinase kinase kinase 4 MeSH D08.811.913.696.620.682.700.559.500 – map kinase kinase kinase 5 MeSH D08.811.913.696.620.682.700.559.800 – proto-oncogene proteins c-mos MeSH D08.811.913.696.620.682.700.559.842 – raf kinases MeSH D08.811.913.696.620.682.700.559.842.249 – oncogene proteins v-raf MeSH D08.811.913.696.620.682.700.559.842.374 – proto-oncogene proteins b-raf MeSH D08.811.913.696.620.682.700.559.842.500 – proto-oncogene proteins c-raf MeSH D08.811.913.696.620.682.700.565 – mitogen-activated protein kinase kinases MeSH D08.811.913.696.620.682.700.565.100 – map kinase kinase 1 MeSH D08.811.913.696.620.682.700.565.200 – map kinase kinase 2 MeSH D08.811.913.696.620.682.700.565.300 – map kinase kinase 3 MeSH D08.811.913.696.620.682.700.565.400 – map kinase kinase 4 MeSH D08.811.913.696.620.682.700.565.500 – map kinase kinase 5 MeSH D08.811.913.696.620.682.700.565.600 – map kinase kinase 6 MeSH D08.811.913.696.620.682.700.565.700 – map kinase kinase 7 MeSH D08.811.913.696.620.682.700.567 – mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.567.342 – extracellular signal-regulated map kinases MeSH D08.811.913.696.620.682.700.567.342.500 – mitogen-activated protein kinase 1 MeSH D08.811.913.696.620.682.700.567.342.750 – mitogen-activated protein kinase 3 MeSH D08.811.913.696.620.682.700.567.342.875 – mitogen-activated protein kinase 6 MeSH D08.811.913.696.620.682.700.567.342.937 – mitogen-activated protein kinase 7 MeSH D08.811.913.696.620.682.700.567.513 – jnk mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.567.513.500 – mitogen-activated protein kinase 8 MeSH D08.811.913.696.620.682.700.567.513.750 – mitogen-activated protein kinase 9 MeSH D08.811.913.696.620.682.700.567.513.800 – mitogen-activated protein kinase 10 MeSH D08.811.913.696.620.682.700.567.878 – p38 mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.586 – oncogene protein v-akt MeSH D08.811.913.696.620.682.700.606 – phytochrome a MeSH D08.811.913.696.620.682.700.646 – proline-directed protein kinases MeSH D08.811.913.696.620.682.700.646.500 – cyclin-dependent kinases MeSH D08.811.913.696.620.682.700.646.500.500 – cdc2-cdc28 kinases MeSH D08.811.913.696.620.682.700.646.500.500.500 – cyclin-dependent kinase 5 MeSH D08.811.913.696.620.682.700.646.500.750 – cyclin-dependent kinase 2 MeSH D08.811.913.696.620.682.700.646.500.875 – cyclin-dependent kinase 4 MeSH D08.811.913.696.620.682.700.646.500.937 – cyclin-dependent kinase 6 MeSH D08.811.913.696.620.682.700.646.625 – glycogen synthase kinase 3 MeSH D08.811.913.696.620.682.700.646.750 – mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.646.750.249 – extracellular signal-regulated map kinases MeSH D08.811.913.696.620.682.700.646.750.249.500 – mitogen-activated protein kinase 1 MeSH D08.811.913.696.620.682.700.646.750.249.750 – mitogen-activated protein kinase 3 MeSH D08.811.913.696.620.682.700.646.750.249.875 – mitogen-activated protein kinase 6 MeSH D08.811.913.696.620.682.700.646.750.249.937 – mitogen-activated protein kinase 7 MeSH D08.811.913.696.620.682.700.646.750.374 – jnk mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.646.750.374.500 – mitogen-activated protein kinase 8 MeSH D08.811.913.696.620.682.700.646.750.374.750 – mitogen-activated protein kinase 9 MeSH D08.811.913.696.620.682.700.646.750.374.800 – mitogen-activated protein kinase 10 MeSH D08.811.913.696.620.682.700.646.750.843 – p38 mitogen-activated protein kinases MeSH D08.811.913.696.620.682.700.725 – protein kinase C MeSH D08.811.913.696.620.682.700.725.100 – protein kinase C-alpha MeSH D08.811.913.696.620.682.700.725.400 – protein kinase C-delta MeSH D08.811.913.696.620.682.700.725.750 – protein kinase C-epsilon MeSH D08.811.913.696.620.682.700.755 – proto-oncogene proteins C-akt MeSH D08.811.913.696.620.682.700.759 – proto-oncogene proteins C-bcr MeSH D08.811.913.696.620.682.700.776 – proto-oncogene proteins C-pim-1 MeSH D08.811.913.696.620.682.700.827 – rhodopsin kinase MeSH D08.811.913.696.620.682.700.862 – ribosomal protein s6 kinases MeSH D08.811.913.696.620.682.700.862.249 – ribosomal protein s6 kinases, 70-kda MeSH D08.811.913.696.620.682.700.862.500 – ribosomal protein s6 kinases, 90-kda MeSH D08.811.913.696.620.682.725 – protein-tyrosine kinase MeSH D08.811.913.696.620.682.725.049 – focal adhesion protein-tyrosine kinases MeSH D08.811.913.696.620.682.725.049.500 – focal adhesion kinase 1 MeSH D08.811.913.696.620.682.725.049.750 – focal adhesion kinase 2 MeSH D08.811.913.696.620.682.725.200 – mitogen-activated protein kinase kinases MeSH D08.811.913.696.620.682.725.200.100 – map kinase kinase 1 MeSH D08.811.913.696.620.682.725.200.200 – map kinase kinase 2 MeSH D08.811.913.696.620.682.725.200.300 – map kinase kinase 3 MeSH D08.811.913.696.620.682.725.200.400 – map kinase kinase 4 MeSH D08.811.913.696.620.682.725.200.500 – map kinase kinase 5 MeSH D08.811.913.696.620.682.725.200.600 – map kinase kinase 6 MeSH D08.811.913.696.620.682.725.200.700 – map kinase kinase 7 MeSH D08.811.913.696.620.682.725.300 – proto-oncogene proteins c-fes MeSH D08.811.913.696.620.682.725.400 – receptor protein-tyrosine kinases MeSH D08.811.913.696.620.682.725.400.020 – fms-like tyrosine kinase 3 MeSH D08.811.913.696.620.682.725.400.024 – receptor, fibroblast growth factor, type 1 MeSH D08.811.913.696.620.682.725.400.037 – receptor, fibroblast growth factor, type 2 MeSH D08.811.913.696.620.682.725.400.043 – receptor, fibroblast growth factor, type 3 MeSH D08.811.913.696.620.682.725.400.046 – receptor, fibroblast growth factor, type 4 MeSH D08.811.913.696.620.682.725.400.050 – proto-oncogene proteins c-kit MeSH D08.811.913.696.620.682.725.400.075 – proto-oncogene proteins c-met MeSH D08.811.913.696.620.682.725.400.087 – proto-oncogene proteins c-ret MeSH D08.811.913.696.620.682.725.400.100 – receptor, epidermal growth factor MeSH D08.811.913.696.620.682.725.400.150 – receptor, erbb-2 MeSH D08.811.913.696.620.682.725.400.175 – receptor, erbb-3 MeSH D08.811.913.696.620.682.725.400.185 – receptor, igf type 1 MeSH D08.811.913.696.620.682.725.400.200 – receptor, insulin MeSH D08.811.913.696.620.682.725.400.500 – receptor, macrophage colony-stimulating factor MeSH D08.811.913.696.620.682.725.400.660 – receptor, trka MeSH D08.811.913.696.620.682.725.400.700 – receptor, trkb MeSH D08.811.913.696.620.682.725.400.800 – receptor, trkc MeSH D08.811.913.696.620.682.725.400.850 – receptors, eph family MeSH D08.811.913.696.620.682.725.400.850.050 – receptor, epha1 MeSH D08.811.913.696.620.682.725.400.850.100 – receptor, epha2 MeSH D08.811.913.696.620.682.725.400.850.150 – receptor, epha3 MeSH D08.811.913.696.620.682.725.400.850.200 – receptor, epha4 MeSH D08.811.913.696.620.682.725.400.850.250 – receptor, epha5 MeSH D08.811.913.696.620.682.725.400.850.300 – receptor, epha6 MeSH D08.811.913.696.620.682.725.400.850.400 – receptor, epha7 MeSH D08.811.913.696.620.682.725.400.850.500 – receptor, epha8 MeSH D08.811.913.696.620.682.725.400.850.600 – receptor, ephb1 MeSH D08.811.913.696.620.682.725.400.850.650 – receptor, ephb2 MeSH D08.811.913.696.620.682.725.400.850.700 – receptor, ephb3 MeSH D08.811.913.696.620.682.725.400.850.750 – receptor, ephb4 MeSH D08.811.913.696.620.682.725.400.850.800 – receptor, ephb5 MeSH D08.811.913.696.620.682.725.400.900 – receptors, platelet-derived growth factor MeSH D08.811.913.696.620.682.725.400.900.500 – receptor, platelet-derived growth factor alpha MeSH D08.811.913.696.620.682.725.400.900.750 – receptor, platelet-derived growth factor beta MeSH D08.811.913.696.620.682.725.400.925 – receptors, tie MeSH D08.811.913.696.620.682.725.400.925.249 – receptor, tie-1 MeSH D08.811.913.696.620.682.725.400.925.500 – receptor, tie-2 MeSH D08.811.913.696.620.682.725.400.950 – receptors, vascular endothelial growth factor MeSH D08.811.913.696.620.682.725.400.950.100 – vascular endothelial growth factor receptor-1 MeSH D08.811.913.696.620.682.725.400.950.200 – vascular endothelial growth factor receptor 2 MeSH D08.811.913.696.620.682.725.400.950.300 – vascular endothelial growth factor receptor-3 MeSH D08.811.913.696.620.682.725.500 – proto-oncogene proteins c-abl MeSH D08.811.913.696.620.682.725.800 – src-family kinases MeSH D08.811.913.696.620.682.725.800.315 – lymphocyte specific protein tyrosine kinase p56(lck) MeSH D08.811.913.696.620.682.725.800.472 – oncogene protein pp60(v-src) MeSH D08.811.913.696.620.682.725.800.551 – proto-oncogene proteins c-fyn MeSH D08.811.913.696.620.682.725.800.590 – proto-oncogene proteins c-hck MeSH D08.811.913.696.620.682.725.800.610 – proto-oncogene proteins c-yes MeSH D08.811.913.696.620.682.725.800.630 – proto-oncogene proteins pp60(c-src) MeSH D08.811.913.696.620.682.725.900 – zap-70 protein-tyrosine kinase MeSH D08.811.913.696.620.685 – pyridoxal kinase MeSH D08.811.913.696.620.695 – pyruvate kinase MeSH D08.811.913.696.620.750 – thymidine kinase MeSH D08.811.913.696.620.800 – uridine kinase MeSH D08.811.913.696.630 – phosphotransferases (carboxyl group acceptor) MeSH D08.811.913.696.630.025 – acetate kinase MeSH D08.811.913.696.630.050 – aspartate kinase MeSH D08.811.913.696.630.050.050 – aspartokinase homoserine dehydrogenase MeSH D08.811.913.696.630.700 – phosphoglycerate kinase MeSH D08.811.913.696.640 – phosphotransferases (nitrogenous group acceptor) MeSH D08.811.913.696.640.025 – arginine kinase MeSH D08.811.913.696.640.150 – creatine kinase MeSH D08.811.913.696.640.150.500 – creatine kinase, bb form MeSH D08.811.913.696.640.150.625 – creatine kinase, mb form MeSH D08.811.913.696.640.150.750 – creatine kinase, mitochondrial form MeSH D08.811.913.696.640.150.875 – creatine kinase, mm form MeSH D08.811.913.696.645 – phosphotransferases (paired acceptors) MeSH D08.811.913.696.645.700 – pyruvate, orthophosphate dikinase MeSH D08.811.913.696.650 – phosphotransferases (phosphate group acceptor) MeSH D08.811.913.696.650.025 – adenylate kinase MeSH D08.811.913.696.650.150 – atp synthetase complexes MeSH D08.811.913.696.650.150.500 – proton-translocating atpases MeSH D08.811.913.696.650.150.500.249 – bacterial proton-translocating atpases MeSH D08.811.913.696.650.150.500.500 – chloroplast proton-translocating atpases MeSH D08.811.913.696.650.150.500.750 – mitochondrial proton-translocating atpases MeSH D08.811.913.696.650.150.500.875 – vacuolar proton-translocating atpases MeSH D08.811.913.696.650.450 – guanylate kinase MeSH D08.811.913.696.650.550 – nucleoside-diphosphate kinase MeSH D08.811.913.696.650.575 – nucleoside-phosphate kinase MeSH D08.811.913.696.900 – transferases (other substituted phosphate groups) MeSH D08.811.913.696.900.074 – CDP-diacylglycerol—inositol 3-phosphatidyltransferase MeSH D08.811.913.696.900.150 – CDP-diacylglycerol—serine O-phosphatidyltransferase MeSH D08.811.913.696.900.200 – diacylglycerol cholinephosphotransferase MeSH D08.811.913.696.900.250 – ethanolaminephosphotransferase
== Function == The protein encoded by this gene is the predominant constituent of the crystalline core of the eosinophil granule. High levels of the proform of this protein are also present in placenta and pregnancy serum, where it exists as a complex with several other proteins including pregnancy-associated plasma protein A (PAPPA), angiotensinogen (AGT), and C3dg. This protein may be involved in antiparasitic defense mechanisms as a cytotoxin and helmintho-toxin, and in immune hypersensitivity reactions. It is directly implicated in epithelial cell damage, exfoliation, and bronchospasm in allergic diseases. PRG2 is a 117-residue protein that predominates in eosinophil granules. It is a potent enzyme against helminths and is toxic towards bacteria and mammalian cells in vitro. The eosinophil major basic protein also causes the release of histamine from mast cells and basophils, and activates neutrophils and alveolar macrophages.
Sources: en.wikipedia.org
A few of the latter are so rare that they were not discovered in nature, but were synthesized in the laboratory before it was determined that they exist in nature: technetium (element 43), promethium (element 61), astatine (element 85), neptunium (element 93), and plutonium (element 94). No element heavier than einsteinium (element 99) has ever been observed in macroscopic quantities in its pure form, nor has astatine; francium (element 87) has been only photographed in the form of light emitted from microscopic quantities. Of the 94 natural elements, eighty have a stable isotope and one more (bismuth) has an almost-stable isotope (with a half-life of 2.01×1019 years, over a billion times the age of the universe). Two more, thorium and uranium, have isotopes undergoing radioactive decay with a half-life comparable to the age of the Earth. The stable elements plus bismuth, thorium, and uranium make up the 83 primordial elements that survived from the Earth's formation. The remaining eleven natural elements decay quickly enough that their continued trace occurrence rests primarily on being constantly regenerated as intermediate products of the decay of thorium and uranium. All 24 known artificial elements are radioactive.
== Preparations == The Gemini 4 spacecraft completed major manufacturing activity, module tests, and equipment installation at McDonnell at the end of January 1965. The spacecraft was mated to the Titan II launch vehicle at Cape Canaveral Launch Complex 19 on April 23, 1965. Final system tests were performed over several additional weeks. NASA leadership approved the Gemini 4 EVA plan on May 25, 1965; the public was informed on the same day
Both types of diabetes, if untreated, result in too much glucose remaining in the blood (hyperglycemia) and many of the same complications. Also, too much insulin and/or exercise without enough corresponding food intake in diabetics can result in low blood sugar (hypoglycemia).
Menkes disease is a congenital disease that is a cause of copper deficiency. Menkes disease is a hereditary condition caused by a defective gene involved with the metabolism of copper in the body. Menkes disease has a wide variety of symptoms including floppy muscle tone, seizures, abnormally low body temperature, and a peculiar steel color hair that feels very rough. Menkes disease is usually fatal, with the majority of affected children dying within the first ten years of life.
Sources: en.wikipedia.org
=== Low FSH levels === Diminished secretion of FSH can result in failure of gonadal function (hypogonadism). This condition is typically manifested in males as failure in production of normal numbers of sperm. In females, cessation of reproductive cycles is commonly observed. Conditions with very low FSH secretions are:
=== Adalimumab === Adalimumab was approved by the FDA in 2002, becoming the first fully human monoclonal antibody to be approved. It was initially used in the treatment of rheumatoid arthritis, but it is now also used in patients with moderate-to-severe Crohn's disease and ulcerative colitis who don't respond well to conventional treatment. Adalimumab showed effectiveness in patients with Crohn's disease, but less than that of infliximab. It was the best selling drug in 2017 with sales upwards of $18 billion.
The first scientists to determine relative atomic masses were John Dalton and Thomas Thomson between 1803 and 1805 and Jöns Jakob Berzelius between 1808 and 1826. Relative atomic mass (Atomic weight) was originally defined relative to that of the lightest element, hydrogen, which was taken as 1.00, and in the 1820s, Prout's hypothesis stated that atomic masses of all elements would prove to be exact multiples of that of hydrogen. Berzelius, however, soon proved that this was not even approximately true, and for some elements, such as chlorine, relative atomic mass, at about 35.5, falls almost exactly halfway between two integral multiples of that of hydrogen. Still later, this was shown to be largely due to a mix of isotopes, and that the atomic masses of pure isotopes, or nuclides, are multiples of the hydrogen mass, to within about 1%. In the 1860s, Stanislao Cannizzaro refined relative atomic masses by applying Avogadro's law (notably at the Karlsruhe Congress of 1860). He formulated a law to determine relative atomic masses of elements: the different quantities of the same element contained in different molecules are all whole multiples of the atomic weight and determined relative atomic masses and molecular masses by comparing the vapor density of a collection of gases with molecules containing one or more of the chemical element in question. In the 20th century, until the 1960s, chemists and physicists used two different atomic-mass scales.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.